My Approach When Prescribing Here's my general framework not a rigid protocol, but a starting point for the conversation: I Tend to Start with Semaglutide When The patient has established cardiovascular disease (because of the SELECT trial data) Insurance covers semaglutide but not tirzepatide The patient has MASH/fatty liver disease Cost is the primary concern and semaglutide is more accessible I Tend to Start with Tirzepatide When Maximum weight loss is the primary goal The patient has type 2 diabetes (tirzepatide shows greater A1C reduction roughly 2.02.5% vs 1.02.0% for semaglutide) The patient has tried semaglutide with insufficient results Insurance covers both options equally Regardless of which medication we choose, I always emphasize that GLP-1 therapy is most effective when combined with nutritional counseling, physical activity, and behavioral support
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.
Cells struggle to produce enough ATP, and you feel it as fatigue, slower recovery, or cognitive fog
doi: 10.3390/ijms23063110 405 GanJZhangXMaCSunLFengYHeZet al
The most important message to get across is that these are products which are not approved for human use, and the risks are much more likely to outweigh the benefits, she says
Siga sempre a orientao do seu profissional de sade
.webp)
